These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37752582)

  • 1. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
    Rodriguez-Mogeda C; van Lierop ZYGJ; van der Pol SMA; Coenen L; Hogenboom L; Kamermans A; Rodriguez E; van Horssen J; van Kempen ZLE; Uitdehaag BMJ; Teunissen CE; Witte ME; Killestein J; de Vries HE
    J Neuroinflammation; 2023 Sep; 20(1):215. PubMed ID: 37752582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
    Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
    Meng D; Sacco R; Disanto G; Widmer F; Jacober SLS; Gobbi C; Zecca C
    Mult Scler; 2024 Jun; 30(7):857-867. PubMed ID: 38767224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
    Rolfes L; Pawlitzki M; Pfeuffer S; Nelke C; Lux A; Pul R; Kleinschnitz C; Kleinschnitz K; Rogall R; Pape K; Bittner S; Zipp F; Warnke C; Goereci Y; Schroeter M; Ingwersen J; Aktas O; Klotz L; Ruck T; Wiendl H; Meuth SG
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34261812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
    Bou Rjeily N; Fitzgerald KC; Mowry EM
    Mult Scler; 2024 Feb; 30(2):257-260. PubMed ID: 37942884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended interval dosing with ocrelizumab in multiple sclerosis.
    Novak F; Bajwa HM; Østergaard K; Berg JM; Madsen JS; Olsen DA; Urbonaviciute I; Illes Z; Stilund ML; Romme Christensen J; Bramow S; Sellebjerg F; Sejbaek T
    Mult Scler; 2024 Jun; 30(7):847-856. PubMed ID: 38646949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
    Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
    Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates.
    Rempe T; Elfasi A; Rodriguez E; Vasquez M; Graves J; Kinkel R
    Mult Scler Relat Disord; 2023 Nov; 79():105028. PubMed ID: 37813071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab.
    Beckers L; Baeten P; Popescu V; Swinnen D; Cardilli A; Hamad I; Van Wijmeersch B; Tavernier SJ; Kleinewietfeld M; Broux B; Fraussen J; Somers V
    Clin Immunol; 2024 Feb; 259():109894. PubMed ID: 38185268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis.
    Schuckmann A; Steffen F; Zipp F; Bittner S; Pape K
    Med; 2023 Jun; 4(6):361-372.e3. PubMed ID: 37236189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
    Zanghì A; Avolio C; Signoriello E; Abbadessa G; Cellerino M; Ferraro D; Messina C; Barone S; Callari G; Tsantes E; Sola P; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Inglese M; D'Amico E
    Neurotherapeutics; 2022 Sep; 19(5):1535-1545. PubMed ID: 36036858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
    Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
    Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
    Toorop AA; Hogenboom L; Bloem K; Kocyigit M; Commandeur NWM; Wijnants A; Lissenberg-Witte BI; Strijbis EMM; Uitdehaag BMJ; Rispens T; Killestein J; van Kempen ZLE
    J Neurol Neurosurg Psychiatry; 2023 Jun; 94(6):487-493. PubMed ID: 36693720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
    Baker D; Pryce G; James LK; Marta M; Schmierer K
    Mult Scler Relat Disord; 2020 Sep; 44():102279. PubMed ID: 32645640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
    Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
    Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience.
    Zanghì A; Ferraro D; Callari G; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Moretti MC; Avolio C; D'Amico E
    Curr Neuropharmacol; 2024; 22(2):339-345. PubMed ID: 37876043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab.
    Abbadessa G; Miele G; Cavalla P; Valentino P; Marfia GA; Signoriello E; Landi D; Bosa C; Vercellino M; De Martino A; Missione R; Sparaco M; Lavorgna L; Lus G; Bonavita S
    Int J Environ Res Public Health; 2021 Aug; 18(15):. PubMed ID: 34360456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.